Roche NimbleGen has formed a strategic alliance with BioDiscovery to offer complete solutions to comparative genomic hybridization (CGH) microarray customers
The new high-density 2.1 million probe (HD2) arrays of Roche NimbleGen combined with industry-leading proprietary software, Nexus Copy Number, of BioDiscovery bring unprecedented power and ease in whole-genome CGH analysis.
As part of this alliance Roche NimbleGen and BioDiscovery will co-market and co-promote their products and services to scientists worldwide.
The companies also plan to present data generated from NimbleGen CGH arrays using Nexus software of BioDiscovery to the research community through a series of seminars.
"This alliance with BioDiscovery will enable Roche NimbleGen to significantly enhance the customer experience by providing complete data analysis solutions for our customers using NimbleGen arrays for CGH analysis.
"At the same time we are excited about the opportunity to develop a strong business relationship with BioDiscovery in offering complete solutions to our customers in genomics and life sciences," said Srini Ramachandra, senior director for software marketing at Roche NimbleGen.
"We are thrilled about working with Roche NimbleGen in providing a complete and validated solution to our customers.
"The powerful combination of our technologies enables scientists to analyse data from millions of probes across thousands of samples to quickly arrive at important biological insights," said Soheil Shams, president of BioDiscovery.
"We look forward to expanding our relationship with Roche NimbleGen and furthering the state of technology in genomics research".
